|
|
||||||||
Eur J Cardiothorac Surg 2000;18:136-142
© 2000 Elsevier Science NL
a Department of Thoracic Surgery, Lille University Hospital, Hôpital Calmette, 1 Rue du Professeur J. Leclercq, 59037 Lille Cédex, France
b Department of Pathology, Lille University Hospital, 59037 Lille, France
Received 30 December 1999; received in revised form 30 March 2000; accepted 18 April 2000.
Corresponding author. Tel.: +33-3-2044-4559; fax: +33-3-2044-4890
e-mail: awurtz{at}chru-lille.fr
| Abstract |
|---|
|
|
|---|
Key Words: Primary sarcoma of the lung Surgery Chemotherapy
| 1. Introduction |
|---|
|
|
|---|
| 2. Materials and methods |
|---|
|
|
|---|
Tumours were graded from 1 to 3, according to the classification of the French Federation of Cancer Centers reported by Coindre, based on tumour differentiation, mitosis count and necrosis [12]. Actuarial survival was determined by the KaplanMeier method, and survival differences were compared by the log-rank test. Age, sex, presence or absence of symptoms, tumour size (less or more than 5 cm), complete resection, histological cell type, stage and histology grade were analyzed as predictors of survival.
| 3. Results |
|---|
|
|
|---|
3.2. Radiological findings and tumour location
Pre-operative chest roentgenograms and computed tomograms (CT) were reviewed for all patients. All tumours were solitary masses. The tumour was located in the right lung in 12 patients, and in the left lung in six. In 15 patients, the tumour presented as a sharply defined density. There was a post-obstruction infiltrate in three patients. The CT showed calcification in one case of malignant histocytofibroma, and cavitation in a leiomyosarcoma (diameter 12 cm) and a rhabdomyosarcoma (diameter 15 cm). A moderate unilateral chest effusion was discovered in four patients.
3.3. Bronchoscopy findings and pre-operative pathological diagnosis
All patients underwent sputum cytology and fiber-optic bronchoscopy. The latter showed a tumour growing in the bronchial lumen in seven cases (39%), a bronchial compression in three (16%) and a normal picture in the remaining eight (44%). Sputum cytology never helped to reach a diagnosis. A correct pre-operative pathological diagnosis was obtained in eight cases (44%): from bronchoscopic biopsy specimens in four, CT-guided percutaneous needle aspiration in two, anterior mediastinotomy in one and thoracoscopy in one. Mediastinoscopy was never performed. The pre-operative pathological diagnosis was false for five patients (28%). No further attempt was made to obtain a pre-operative histological diagnosis for five patients, because they were heavy smokers with peripheral nodules strongly suspected to be lung carcinoma.
3.4. Pre-operative treatments
Fifteen patients (83%) underwent surgery without any pre-operative treatment, because CT scan data indicated that their lung sarcoma was completely resectable. In two patients with pre-operative diagnoses of undifferentiated sarcoma and rhabdomyosarcoma ascertained by anterior mediastinotomy (patients 1 and 8 in Table 1), CT scan showed signs of unresectability, i.e. stenosis of the right pulmonary artery and invasion of the left auricle in patient 1, and a huge mass invading the whole chest cavity in patient 8 (Figs. 1 and 2)
. These two patients received six cycles of chemotherapy comprising ifosfamide, doxorubicin, dacarbazine and mesna, which reduced tumour volume by up to 50%. They underwent complete resection of their lung sarcoma 6 weeks after the end of chemotherapy, with disease-free resection margins in patient 8 and only microscopical invasion of the left auricle in patient 1.
|
|
|
3.5. Operative strategy and surgical results
All patients underwent macroscopically complete resection. Lobectomy was performed in 12 patients (66%). It was extended to the chest wall in two of them, and to the diaphragm in two others. Six patients (33%) underwent pneumonectomy which was extended to the chest wall in one and to the superior vena cava and partial left auricle, without cardiopulmonary bypass support, in another (patient 1). Overall, six patients (33%) had extended surgical resection including three chest wall resections (two ribs in two cases and three ribs in one case). Systematic mediastinal lymphadenectomy was done in every case. Operative and 30 days post-operative mortality were nil. Thirty days post-operative morbidity was 33% and included pulmonary infections not requiring assisted ventilation (n=3), air leaks requiring prolonged chest drainage for more than 6 days (n=2) and auricular fibrillation (n=1). The mean hospital stay lasted 11 days (range 724 days).
3.6. Pathology results
The mean diameter of the tumours was 8.05 cm (range 2.515 cm). Four tumours (22%) had a diameter of less than 5 cm and one of less than 3 cm. In seven cases, tumours only invaded the pulmonary parenchyma, and in seven cases, the parenchyma and at least one large bronchial lumen. None of the tumours was restricted to the bronchial lumen. In patient 8 (rhabdomyosarcoma of 15 cm in diameter), patient 4 (malignant fibrous histiocytoma of 10 cm in diameter) and patient 13 (fibrosarcoma of 7 cm in diameter) whose tumours were invading the chest wall, the tumour was considered as primary sarcoma of the lung because over 95% of the tumoural volume was located in the lung. Two patients (11%) had positive resection margins (patients 1 and 13) and patient 13 had at least one positive hilar lymph node (N1 involvement). No patient had N2 involvement. In patient 1, who received pre-operative chemotherapy for a grade 2 undifferentiated sarcoma of uncertain resectability, the left auricle was infiltrated by some malignant cells. In patient 13, who had chest wall resection for grade 3 fibrosarcoma, parts of the chest wall margins were invaded.
3.7. Post-operative treatments
Patients 1 and 13, who had microscopically invaded resection margins, were treated by radiotherapy alone. Four patients had post-operative chemotherapy for presumably poor pathological prognostic factors, i.e. large undifferentiated grade 3 tumours.
3.8. Follow-up and recurrence
The follow-up period ranged from 2 to 144 months (mean 46 months). Sarcoma recurred in eight patients (44%) as a local relapse and metastatic spread in three, as a metastatic spread only in three, and as a local relapse only in two patients (see Table 1). Three patients (16.6%) underwent repeat surgical resection of their recurrent sarcomas: in patients 6 and 9, we resectioned pulmonary metastases, and in patient 15, the previous thoracotomy scar. The two patients who received neoadjuvant chemotherapy for previously unresectable tumours are alive, without recurrent disease, 20 and 58 months after surgery, respectively.
3.9. Survival
Five patients (27.7%) died of recurrent sarcoma after a mean period of 17 months (range 348 months). Four other patients (22.2%) died of non-tumour-related causes. Nine patients (50%) are still alive, six of them free of recurrent disease, and three with recurrent disease which was completely resected in two cases. The third patient who had completely resected recurrent disease died 144 months after the first intervention of non-tumour-related causes. The overall median survival period was 48 months, and actuarial 5-year survival 43%. There was a significant correlation between stage and survival: patients with stage I sarcoma had a better survival than patients with stage IIb (P<0.05). Tumour grade and diameter were not found to affect survival. Histological subtype, T factor, lymph node involvement and the presence of microscopical involvement of the resection margins comprised too few subjects to allow the calculation of statistical trends. Pathological findings and outcome are given for the 18 patients in Table 1.
| 4. Discussion |
|---|
|
|
|---|
|
4.2. Pre-operative chemotherapy and adjuvant treatment
MacCormack and Martini showed that the 29 patients in their series who underwent complete surgical resection survived significantly longer than the eight who received radiotherapy and the five who had no treatment [5]. Regnard and co-workers confirmed that the most important predictor of survival was completeness of resection [9]. In this setting, we first report the cases of two patients with definitely unresectable primary lung sarcomas, for whom pre-operative chemotherapy allowed macroscopically complete resection in both cases, and microscopically complete resection in one case (Figs. 1 and 2). These two patients were alive and free of recurrent disease 20 and 58 months after surgery, respectively. We could not find any other series including patients who had pre-operative chemotherapy before resection of primary lung sarcoma. Only Wu, in a case report, stated that pre-operative chemotherapy was used for a patient at high surgical risk for resectable haemangiopericytoma [15].
The criteria that justify post-operative radiotherapy or chemotherapy, and their impact on survival, cannot as yet be determined because they were given to different proportions of patients in the series reported in the literature. Generally, as in our series, they were justified by incomplete resection, invaded margins, lymph node involvement, and high-grade or large tumours.
4.3. Surgical management
As radical resection with pathological free margins is, when possible, the best option, segmentectomies or wedge resections when done for small peripheral tumours seem to raise the recurrence rates [6,16]. Consequently, when the tumour is unique, lobectomy or, when necessary, pneumonectomy, remains the gold standard. Due to the high percentage of large tumours in most series, resections extended to the chest wall, diaphragm, superior vena cava or auricle included six out of 18 patients in our series and six out of 19 for Bacha and colleagues [8], who reported the use of cardiopulmonary bypass in three patients with negative resection margins in two of them. Primary lung sarcomas rarely disseminate to lymph nodes, but Regnard and co-workers found N2 involvement in two out of 20 resected patients, and N1 involvement in three [9]. This justifies systematic mediastinal lymph node dissection like that performed for any lung cancer, mainly for staging purposes but also with a curative intent [9].
4.4. Pathological results
In our study, MFH was the most common histological cell type diagnosed with undifferentiated sarcoma, but in a smaller proportion of patients than in the series reported by Bacha and co-workers [8]. However, in all the other series for which pathological results were given, leiomyosarcoma was the most commonly reported form of primary pulmonary sarcoma [3,5,6]. After complete surgical resection for MFH, Lee et al. [17] reported better survival than after resection for other sarcomas, but no other data seem to support this report. It is questionable to state whether the three sarcomas which were both in the chest wall and the lung should be considered as primary sarcomas of the lung or as chest wall sarcomas. As a matter of fact, no pathological studies can rule out the precise origin of such sarcomas (malignant fibrous histiocytoma, fibrosarcoma and rhabdomyosarcoma). In accord with Regnard and associates, we considered these lesions, in whom the chest wall invasion was minimal as compared with the lung involvement, as primary sarcomas of the lung [9,18].
4.5. Prognostic factors
As already stated, complete macroscopical resection is the basis of any treatment with a curative aim in the field of primary lung sarcomas, but the impact on survival of microscopically invaded margins remains unclear, chiefly because it is rarely mentioned in the different studies. Accordingly, only Bacha and co-workers reported that six patients out of 20 had positive resection margins [8]. Tumour size was the most commonly individualized prognostic factor. A size larger than 5 cm, according to Nascimento et al. [3], and larger than 4 cm according to Jansen and co-workers [6], indicated a poor prognosis. In the series treated by MacCormack and Martini and reported by Burt and Zakowski [5], there was also a trend towards better survival for patients with tumours with a diameter of 5 cm or less. Like Regnard and Bacha [8,9], we did not find that tumour size was of prognostic significance, probably because of the few small tumours in these three series. Only Jansen and co-workers demonstrated that grade 3 sarcomas had a worse prognosis than grade 1 sarcomas [6]. The present study confirms the prognostic significance of the revised TNM international lung cancer staging system [11] when applied to primary pulmonary sarcomas, as shown by Regnard and co-workers [9]. Nevertheless, this factor was not studied in any other series.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
E. J. Esaka, J. U. Celebrezze, S. H. Golde, G. Chiossi, and R. L. Thomas Pulmonary Synovial Sarcoma Presenting as a Pneumothorax During Pregnancy Obstet. Gynecol., February 1, 2008; 111(2): 555 - 558. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Wiebe, H. Baraki, P. Macchiarini, and A. Haverich Extended pulmonary resections of advanced thoracic malignancies with support of cardiopulmonary bypass Eur. J. Cardiothorac. Surg., April 1, 2006; 29(4): 571 - 577. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Zonta, F. Lovisetto, P. Morbini, L. Cobianchi, and S. Nazari Thoracic-Abdominal Approach in Primary Pulmonary Synovial Sarcoma Asian Cardiovasc Thorac Ann, March 1, 2005; 13(1): 85 - 87. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Park, M. Bacchetta, M. S. Bains, R. J. Downey, R. Flores, V. W. Rusch, and L. N. Girardi Surgical management of thoracic malignancies invading the heart or great vessels Ann. Thorac. Surg., September 1, 2004; 78(3): 1024 - 1030. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.B. Petrov, V.I. Vlassov, G.T. Kalaydjiev, M.A. Plochev, E.D. Obretenov, V.I. Stanoev, and S.E. Danon Primary pulmonary sarcomas and carcinosarcomas - postoperative results and comparative survival analysis Eur. J. Cardiothorac. Surg., April 1, 2003; 23(4): 461 - 466. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Fischer, M. de Perrot, Y. Sekine, and S. Keshavjee Long-term survival after multiple resections of a fibrosarcoma involving the lung and chest wall Eur. J. Cardiothorac. Surg., August 1, 2001; 20(2): 421 - 423. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |